{"i": ["DNA prime / rAd5 boost vaccine", "EraMune 02", "biotin - SP", "VRC - HIVDNA016 - 00 - VP priming ( DNA prime , consisting of envA , envB , envC , gagB , polB , nefB ) vaccinations", "envA , envB , envC , gagB , polB , nefB )", "VRC - HIVADV014 - 00 - VP ( rAd5 boost", "TZM - bl reporter cells ( ATCC , PTA - 5659 )", "HIV DNA vaccine", "ART intensification", "DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine", "HIV DNA prime - rAd5 boost vaccine ( containing VRC - HIVDNA016 - 00 - VP and VRC - HIVADV014 - 00 - VP", "HIV Env or VSV - g complementation plasmid using polyethyleneimine ( PEI )", "ritonavir .", "NNRTI + PI", "HIV - rAd5 boost", "DNA prime - and envelope protein boost combinations", "Biojector 2000 injection system", "HIV DNA prime and rAd5 boost vaccine", "VRC - HIVDNA016 - 00 - VP", "raltegravir .", "six plasmid DNA prime ( envA , envB , envC , gagB , polB , nefB ) and rAd5 boost HIV vaccine", "ALVAC - HIV and AIDSVAX B / E ( gp120 ) vaccine", "VRC - HIVADV014 - 00 - VP .", "multi - clade ( A , B , and C ) rAd5 vector boost", "NNRTI = non - nucleoside reverse transcriptase inhibitor", "DNA prime - recombinant adenovirus 5 ( rAd5 ) boost HIV vaccine", "DNA prime - rAd5 boost vaccine", "RAL / MVC / vaccine", "raltegravir", "NRTI + NNRTI + PI / r", "NNRTI", "HIV - 1 Env - deleted backbone plasmid pSG3\u0394Env ( NIHARRRP", "suppressive ART", "needle and syringe", "ART = antiretroviral therapy", "DNA prime - rAd5 boost", "DNA prime - rAd5 boost vaccination", "ADCC", "DNA prime - rAd5 boost HIV vaccine", "nucleoside", "maraviroc", "Antiretroviral therapy ( ART )"], "o": ["HIV - 1JR - FL IC50 ' s", "EnvB antibody responses", "signal intensities", "baseline IC50 values", "intracellular protease activity ( dead cell protease )", "potency", "HIV - specific antibodies", "neutralization potency or ADCC efficacy .", "Percent cytotoxicity", "total CD4 + cell associated HIV DNA", "HIV - 1 neutralization potency and ADCC activity", "HIV disease progression", "EnvB specific antibody titers", "neutralization of HIV - 1JR - FL and signal intensity or antibody titer", "HIV RNA levels", "Luminescence in relative light units ( RLU )", "median baseline total cell - associated HIV DNA", "ADCC IgG", "antibody signals or ELISA titers .", "virus neutralization", "antigen specific antibody levels", "immunogenicity", "median nadir CD4 + cell count", "immune response", "antibody signal levels", "EnvB signal intensities", "antibody signals or ELISA titers", "CD4 + and CD8 + IFN - \u03b3 ELISpot responses", "antibody signals", "HIV acquisition", "activity", "cross clade HIV - 1 specific antibody binding signals", "antibody response", "IC50 levels", "HIV - specific antibody responses", "antibody binding levels", "antibody signal intensities", "low - titer neutralizing antibodies", "EnvB specific antibody levels", "neutralization ( IC50 ) values and ADCC activity .", "neutralization potency", "cross - clade HIV - specific antibody response", "HIV - specific antibody - dependent cellular cytotoxicity ( ADCC ) responses", "antibody levels", "coated CEM cells", "% ADCC of HIV - 1SF162 infected cells", "antibody signals / titers and ADCC activity .", "risk of HIV infection", "% ADCCSOSIP trimer and IC50 ' s or % ADCCJR - FL and IC50 ' s .", "latent viral reservoir", "cytotoxicity", "EnvB intensities", "Antibody binding levels", "cytotoxic T - lymphocyte responses", "antibody neutralization or ADCC .", "CD8 + T cell responses", "ADCC activity and cross clade signal intensities or ELISA titers", "EnvA and EnvC subtype - specific antibody titers", "EnvB antibody signal intensities", "signal intensities against EnvA", "% ADCCSF162 and IC50 HIV - 1JR - FL", "ADCC activities", "total CD4 + cell - associated HIV DNA", "neutralization , antibody titers , and ADCC .", "pooled clade A , B , and C envelope antibody titers", "neutralization", "EnvC - specific antibody signal intensities", "HIV - 1SF162 IC50 values", "neutralizing antibody responses", "Antibody - binding signals", "antibody neutralization potency", "binding to peptides", "cross clade ELISA titers", "cross clade HIV - 1 specific antibody response", "median baseline CD4 + cell count", "ADCC activity", "pooled clade A , B , or C envelope antibody titers", "% ADCCSF162 and IC50 HIV - 1SF162", "EnvB antibody levels", "cross clade antibody titers", "neutralization or ADCC responses .", "neutralization efficiency and antibody - dependent cellular cytotoxicity ( ADCC ).", "IC50 values", "Virus production", "IC50", "Tier 2 neutralization", "EnvB specific baseline antibody signal levels", "antibody - binding signals", "signal intensity", "HIV - specific antibody titer , neutralization , and ADCC"]}